Tekla Research Revenue and Competitors
Estimated Revenue & Valuation
- Tekla Research's estimated annual revenue is currently $56.2M per year.
- Tekla Research's estimated revenue per employee is $338,800
Employee Data
- Tekla Research has 166 Employees.
- Tekla Research grew their employee count by 16% last year.
Tekla Research Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $9.4M | 38 | -16% | N/A | N/A |
#2 | $207.5M | 539 | 5% | N/A | N/A |
#3 | $63M | 186 | 3% | N/A | N/A |
#4 | $5.2M | 24 | -4% | N/A | N/A |
#5 | $27.1M | 88 | -17% | N/A | N/A |
#6 | $42.2M | 137 | 30% | N/A | N/A |
#7 | $8.4M | 34 | 26% | N/A | N/A |
#8 | $3.3M | 18 | -10% | N/A | N/A |
#9 | $20.2M | 73 | -1% | N/A | N/A |
#10 | $25.9M | 84 | -13% | N/A | N/A |
What Is Tekla Research?
Tekla Research is a company at the forefront of aviation defense technology for over a decade. Founded in 1995, Tekla Research is a Service-Disabled Veteran-Owned Small Business, with a team of talented, experienced, and dedicated individuals offering the highest quality service and dependability. Our employees have an average of 20 years of military/government experience on military avionics integration and testing.
keywords:N/AN/A
Total Funding
166
Number of Employees
$56.2M
Revenue (est)
16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Tekla Research News
Finally, Qube Research & Technologies Ltd acquired a new position in Tekla Healthcare Investors during the fourth quarter worth $597,000.
Despite pharma and biotech research being all over the news for two ... Tekla Healthcare Investors (HQH) was established in 1987 and is...
Tekla Healthcare Investors (NYSE:HQH) is a close ended healthcare ... you can enter any ticker and get extensive curated research material.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $71.1M | 223 | -8% | N/A |
#2 | $210.9M | 837 | N/A | N/A |
#3 | $170.9M | 1221 | 8% | N/A |
#4 | $300M | 2801 | 16% | N/A |